摘要
Abstract
Objective To analyze the clinical value of combined testing of serum neuron specific enolase(NSE),cytokeratin-19-fragment(CYFRA21-1),carcinoembryonic antigen(CEA),and squamous cell carcinoma antigen(SCC)in the early diagnosis of lung cancer.Methods A total of 70 patients with lung cancer(the lung cancer group)and 64 patients with benign lung lesions(the benign group)admitted to Yangjiang Hospital of Traditional Chinese Medicine from January 2021 to December 2022,and 70 healthy physical examiners(the control group)during the same period were selected for retrospective analysis.All subjects received serum NSE,CYFRA21-1,CEA,and SCC tests.The test results of the three groups of subjects were analyzed,and the diagnostic sensitivity,specificity,and accuracy of serum markers were analyzed.Results The serum NSE,CEA,CYFRA21-1,and SCC indicators in the lung cancer group were higher than those in the control group and the benign group(P<0.05).According to different pathological classifications,70 patients in the lung cancer group were divided into 29 cases of small cell carcinoma and 41 cases of non-small cell lung cancer.CEA,CYFRA21-1,and SCC in patients with non-small cell carcinoma were higher than those in patients with small cell carcinoma,and NSE were lower than those in patients with small cell carcinoma,with statistically significant differences(P<0.05).The sensitivity and accuracy of combined diagnosis were higher than those of single test,with statistically significant differences(P<0.05).Conclusion For patients with lung cancer,early use of combined testing of serum NSE,CYFRA21-1,CEA,and SCC has a positive significance,which can effectively improve the sensitivity and accuracy of diagnosis,providing reliable reference for clinical doctors.关键词
肺癌/早期诊断/联合检测/血清肿瘤标志物Key words
Lung cancer/Early diagnosis/Combined testing/Serum tumor markers分类
医药卫生
